AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
  • Age: Between 1 Year(s) - 21 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Newly diagnosed de novo ALL (B-ALL or T-ALL) with definitive evidence of BCR-ABL1 fusion by karyotype, FISH and/or RT-PCR.

You may not be eligible for this study if the following are true:

  • 1) Known history of chronic myelogenous leukemia (CML). 2) ALL developing after a previous cancer treated with cytotoxic chemotherapy. 3) Active, uncontrolled infection or active systemic illness that requires ongoing vasopressor support or mechanical ventilation 4) Down syndrome 5) Pregnancy and Breast Feeding. a. Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential. b. Lactating females who plan to breastfeed their infants. c. Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.